Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Do we really need mitomycin for ASLA (advanced surface laser ablation)

Poster Details

First Author: A.Zafar GREECE

Co Author(s):    I. Asslanides                    

Abstract Details

Purpose:

The aim of the current study is to compare accelerated CXL (2.4 J/cm�Â�²) in one eye to MMC (0.02%) in the contralateral eye in patients undergoing Trans-PRK for myopia. The purpose is to evaluate the efficacy of the two different techniques given that the use of CXL, even though it is more expensive that MMC, offers a strengthened post-operative cornea and replaces the MMC that is toxic and can potentially cause damage to the patient.

Setting:

The patients were recruited at Emmetropia Mediterranean Eye Institute, which is a refractive surgery institute in Crete, Greece between 2012 and 2016. Emmetropia Eye institute, Pl. Eleftherias 44, Iraklio 712 01 Heraklion, Crete, Greece

Methods:

This was an evaluation of a prospective study consisted of 34 eyes of 17 (8 males, 9 females). The patients�â�€�™ mean age was 26.88 years (SD 6.04, range 19�â�€�“36 years). All the patients were myopic (range: -2.75 to -10.5 D) undergoing Tran-sPRK (ASLA) treatment. One of the two treated eyes of each patient was randomly selected to receive CXL treatment whereas on the other one MMC was applied immediately after the treatment.

Results:

In none of the major post-operative time stamps (1 month, 3 months, 6 months, 12 months) was any statistically significant difference between the two groups regarding the UDVA. At all the time points the haze scores difference was not statistically significant between the two groups.

Conclusions:

There is no difference between the UDVA and corneal haze at all the time points during follow up. Mitomycin is toxic to the tissues however corneal cross linkage is a much safer procedure, and give the same results as combining it with Mitomycin.

Financial Disclosure:

NONE

Back to Poster listing